Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1670-1686

  Hunninghake, Donald B ^a   Ballantyne, Christie M ^b   Maccubbin, Darbie L ^c   Shah, Arvind K ^c   Gumbiner, Barry ^c   Mitchel, Yale B ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Metabolic syndrome; Simvastatin; Triglycerides

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; EDUCATION PROGRAM; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 0037707297     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80162-5     Document Type: Article

References (24)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
2. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
3. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol. 1998;14(Suppl B):14B-17B.
4. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(Suppl M):M8-M14.
5. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124(Suppl):S11-S20.
6. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95:69-75.
7. Krauss RM. Triglycerides and atherogenic lipoproteins: Rationale for lipid management. Am J Med 1998;105(Suppl 1A):58S-62S.
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
10. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation. 1998;97:946-952.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
12. Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000;86:221-223.
13. Illingworth DR, Crouse JR 3rd, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50.
14. Lean ME, Han T5, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-161.
15. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
16. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: A review of five comparative studies. Int J Cardiol. 2002;84:53-57.
17. Austin MA, Breslow JL, Hennekins CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
18. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
19. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-1937.
20. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL partide size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) Study. Arterioscler Thromb Vasc Biol. 2000;20:2140-2147.
21. Friedlander Y, Kidron M, Caslake M, et al. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 2000;148:141-149.
22. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
23. Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes. 2002;110: 182-187.
24. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein. (LDL): A new look. Int J Cardiol. 2000;74(Suppl 1):S17-S22.